Development and in vitro characterization of polymeric nanoparticles containing recombinant adrenomedullin-2 intended for therapeutic angiogenesis.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorQuadros, Helenita Costa-
Autor(es): dc.creatorSantos, Laís de Macêdo Ferreira-
Autor(es): dc.creatorMeira, Cássio Santana-
Autor(es): dc.creatorKhouri, Mariana Ivo-
Autor(es): dc.creatorMattei, Bruno-
Autor(es): dc.creatorSoares, Milena Botelho Pereira-
Autor(es): dc.creatorBorges, William de Castro-
Autor(es): dc.creatorFarias, Leonardo Paiva-
Autor(es): dc.creatorFormiga, Fabio Rocha-
Data de aceite: dc.date.accessioned2025-08-21T15:25:48Z-
Data de disponibilização: dc.date.available2025-08-21T15:25:48Z-
Data de envio: dc.date.issued2020-04-24-
Data de envio: dc.date.issued2020-04-24-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/handle/123456789/12099-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0378517319310580?via%3Dihub-
Fonte completa do material: dc.identifierhttps://doi.org/10.1016/j.ijpharm.2019.118997-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1014428-
Descrição: dc.descriptionCardiovascular diseases (CVD) are the leading cause of death worldwide. Growth factor therapy has emerged as novel therapeutic strategy under investigation for CVD. In this sense, adrenomedullin-2 (ADM-2) has been recently identified as a new angiogenic factor able to regulate the regional blood flow and cardiovascular function. However, the therapeutic value of ADM-2 is limited by its short biological half-life and low plasma stability. Poly (lactic-co-glycolic acid) (PLGA) micro- and nanoparticles have been investigated as growth factor delivery systems for cardiac repair. In this study, we aimed to develop PLGA nanoparticles containing ADM-2 intended for therapeutic angiogenesis. PLGA nanoparticles containing ADM-2 were prepared by a double emulsion modified method, resulting in 300 nm-sized stable particles with zeta potential around – 30 mV. Electron microscopy analysis by SEM and TEM revealed spherical particles with a smooth surface. High encapsulation efficiency was reached (ca.70%), as quantified by ELISA. ADM-2 associated to polymer nanoparticles was also determined by EDS elemental composition analysis, SDS-PAGE and LC-MS/MS for peptide identification. In vitro release assays showed the sustained release of ADM-2 from polymer nanoparticles for 21 days. Cell viability experiments were performed in J774 macrophages and H9c2 cardiomyocyte cells, about which PLGA nanoparticles loaded with ADM-2 did not cause toxicity in the range 0.01–1 mg/ml. Of note, encapsulated ADM-2 significantly induced cell proliferation in EA.hy926 endothelial cells, indicating the ADM-2 bioactivity was preserved after the encapsulation process. Collectively, these results demonstrate the feasibility of using PLGA nanoparticles as delivery systems for the angiogenic peptide ADM-2, which could represent a novel approach for therapeutic angiogenesis in CVD using growth factor therapy.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectPoly (lactic-co-glycolic acid)-
Palavras-chave: dc.subjectProtein delivery-
Título: dc.titleDevelopment and in vitro characterization of polymeric nanoparticles containing recombinant adrenomedullin-2 intended for therapeutic angiogenesis.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.